Comparison of famotidine with cimetidine and ranitidine
- PMID: 2896559
Comparison of famotidine with cimetidine and ranitidine
Abstract
The pharmacodynamic, therapeutic, and toxicologic properties of famotidine are evaluated and compared with those of cimetidine and ranitidine. Famotidine, an H2-receptor antagonist with a thiazole nucleus, is approximately 7.5 times more potent than ranitidine and 20 times more potent than cimetidine on an equimolar basis. Therapeutic trials indicate that famotidine 20 mg b.i.d. or 40 mg at bedtime is as effective as standard doses of cimetidine and ranitidine for healing duodenal ulcers. A dose of 40 mg at bedtime appears to heal benign gastric ulcers. A single nocturnal dose of 20 mg is effective in preventing duodenal ulcer relapse. Further studies are required that compare the efficacy of famotidine with cimetidine and ranitidine in the treatment of gastric ulcers and in the prevention of recurrent duodenal ulcers. The overall incidence of adverse effects observed with famotidine appears to be similar to that reported for cimetidine and ranitidine. Like ranitidine, famotidine does not have antiandrogenic effects or substantially inhibit the hepatic metabolism of drugs. Because of its increased antisecretory potency and lack of antiandrogenic effects at higher doses, famotidine may be the H2-receptor antagonist of choice in treating Zollinger-Ellison syndrome. Additional clinical experience, as well as cost and safety factors, will determine the place of famotidine in treating and preventing acid-peptic disorders.
Similar articles
-
Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.Am J Gastroenterol. 1987 Jun;82(6):504-6. Am J Gastroenterol. 1987. PMID: 2883885
-
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.Drugs. 1986 Sep;32(3):197-221. doi: 10.2165/00003495-198632030-00001. Drugs. 1986. PMID: 2875864 Review.
-
Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.Drugs. 1989 Oct;38(4):551-90. doi: 10.2165/00003495-198938040-00005. Drugs. 1989. PMID: 2573505 Review.
-
Pharmacology of H2-receptor antagonists: an overview.J Int Med Res. 1989;17 Suppl 1:9A-16A. J Int Med Res. 1989. PMID: 2566544 Review.
-
Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.Gastroenterology. 1985 Apr;88(4):1026-33. doi: 10.1016/s0016-5085(85)80024-x. Gastroenterology. 1985. PMID: 2857672
Cited by
-
Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial.Strahlenther Onkol. 2014 Aug;190(8):739-44. doi: 10.1007/s00066-014-0602-8. Epub 2014 Mar 12. Strahlenther Onkol. 2014. PMID: 24619016 Clinical Trial.
-
Protective effect of ginsenoside Re on acute gastric mucosal lesion induced by compound 48/80.J Ginseng Res. 2014 Apr;38(2):89-96. doi: 10.1016/j.jgr.2013.10.001. Epub 2013 Dec 18. J Ginseng Res. 2014. PMID: 24748832 Free PMC article.
-
Histamine H1 and H2 receptors are essential transducers of the integrative exercise training response in humans.Sci Adv. 2021 Apr 14;7(16):eabf2856. doi: 10.1126/sciadv.abf2856. Print 2021 Apr. Sci Adv. 2021. PMID: 33853781 Free PMC article.
-
The influence of craniofacial growth in a case of transverse facial cleft.J Orofac Orthop. 2006 May;67(3):215-24. doi: 10.1007/s00056-006-0602-0. J Orofac Orthop. 2006. PMID: 16736122 English, German.